Skip to main navigation Skip to content

Search whole site

Back to all Current clinical trials
Phenylketonuria (PKU): An early phase trial of a new treatment for PKU

PKU is an inherited disease involving loss of the body's ability to metabolise a common amino acid in food called phenylalanine.  Accumulation of toxic byproducts can damage the nervous system, leading to intellectual disability, cognitive impairment and mood disorders.  Available treatments, include strict dietary restrictions and drugs, are difficult to maintain and not always effective.

This study is trialing a novel drug, called JNT-517, which works by increasing excretion of phenylalanine in the urine to reduce circulating levels in the blood. It is anticipated that doing so should limit the toxic effects of phenylalanine byproducts on the nervous system, to provide a more effective and safe treatment for PKU. JNT-517 has been tested in healthy volunters.  This is the first study to test its safety and effectiveness in patients with PKU.

  • Category
  • Trial status
    Active, not recruiting
  • Trial phase
    Phase 1 Drug Trial
    Early stage studies seeking initial evidence of safety, dosage and efficacy in small numbers of patients or healthy volunteers.
  • Registry listing
  • ERM Project ID
    99340

Trial contact details

What you need to know

Who can take part?

The study is open to participants who meet the following criteria:
•    People aged 18 and over with a confirmed medical diagnosis of PKU
•    Must discontinue any drugs for PKU (sapropterin "Kuvan") prior to enrolling in the study
•    Must be willing to observe dietary restrictions for the duration of the study
•    Must agree to avoid pregnancy while on the study
•    Any psychiatric illness must be well controlled for the past 6 months
•    Certain medical conditions may prevent participation, as determined by the study doctor
•    Use of alcohol or other drugs of abuse may prevent participation

What is involved for you?

Study participants will undertake the following procedures, tests and assessments:
•    Weekly clinic visits for five weeks
•    Take oral tablets containing JNT-517 two times a day for four weeks
•    Physical exam and medical history to confirm eligibility
•    Blood and urine tests
•    Pregnancy tests in women who can have children
•    Electrocardiograms
•    Maintain a food diary

Back to all Current clinical trials